Publicacións en colaboración con investigadores/as de Pierre and Marie Curie University (52)

2024

  1. Can gait patterns be explained by joint structure in people with and without radiographic knee osteoarthritis? Data from the IMI-APPROACH cohort

    Skeletal Radiology, Vol. 53, Núm. 11, pp. 2409-2416

  2. Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials

    Seminars in Arthritis and Rheumatism, Vol. 65

2023

  1. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

    Annals of the rheumatic diseases, Vol. 82, Núm. 5, pp. 698-709

  2. Exploring the differences between radiographic joint space width and MRI cartilage thickness changes using data from the IMI-APPROACH cohort

    Skeletal Radiology, Vol. 52, Núm. 7, pp. 1339-1348

  3. Machine-learning predicted and actual 2-year structural progression in the IMI-APPROACH cohort

    Quantitative Imaging in Medicine and Surgery, Vol. 13, Núm. 5, pp. 3298-3306

  4. Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers

    Annals of the Rheumatic Diseases

  5. Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Mulhearn et al

    Annals of the Rheumatic Diseases

  6. Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Rosenbaum et al

    Annals of the Rheumatic Diseases

  7. Test–retest precision and longitudinal cartilage thickness loss in the IMI-APPROACH cohort

    Osteoarthritis and Cartilage, Vol. 31, Núm. 2, pp. 238-248

2022

  1. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

    The Lancet Rheumatology, Vol. 4, Núm. 9, pp. e603-e613

  2. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

    RMD Open, Vol. 8, Núm. 2

  3. GaitSmart motion analysis compared to commonly used function outcome measures in the IMI-APPROACH knee osteoarthritis cohort

    PLoS ONE, Vol. 17, Núm. 3 March

  4. Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and uptake

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 10, pp. 1344-1347

  5. Intra-articular therapies: patient preferences and professional practices in European countries

    Rheumatology International, Vol. 42, Núm. 5, pp. 869-878

  6. Osteoarthritis endotype discovery via clustering of biochemical marker data

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 5, pp. 666-675

  7. Predicted and actual 2-year structural and pain progression in the IMI-APPROACH knee osteoarthritis cohort

    Rheumatology (Oxford, England), Vol. 62, Núm. 1, pp. 147-157

  8. Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera

    Annals of the Rheumatic Diseases

  9. SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases

    Annals of the rheumatic diseases

  10. SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry

    RMD Open, Vol. 8, Núm. 2

  11. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

    Annals of the rheumatic diseases, Vol. 81, Núm. 5, pp. 695-709